Having read through today's Investor Presentation, it would appear that the purpose of the capital raise is to finance the acquisition of the remaining 34.62% interest in the M5 West concession.
At a purchase price of 468mA$, and factoring in a) 47mA$ in transaction costs, and b) incremental proportional debt of 200mA$ for the asset (see slide 57), the M5 West is being valued at 715mA$/34.62% = 2,065mA$ (on a 100% basis).
As shown on slide 46, FY19 underlying EBITDA for the M5 West was 164mA$ for a 65.38% share, i.e. 251mA$ on a 100% basis.
Also, as mentioned on slide 17, the M5 West concession expires on 10 December 2026; after that, the asset will be handed over to the Westconnex (where TCL have already paid for their 25.5% interest).
Therefore, TCL are effectively acquiring the minority interests in the M5 West at an EV/EBITDA of 2065mA$/251mA$ = 8.2x, for an underlying concession that has a residual life of only 7.5 years.
At the current traffic growth rate of +2.4% pa, and CPI growth rate of +1.6% pa, that gives me an IRR (on EV) of just 2.2% pa.
So, while there may well be “operational synergies to be realised” as well as some possible tax savings (as stated on slide 17), at a first glance this looks to me like a very high price to pay for this acquisition, and not accretive at all in terms of asset IRR vis-a-vis Group IRR.
The optical “accretion” (as claimed by Management) by 3c/share in FY20 FCF is merely due to the short life of the underlying concession, but that will be offset by a dilution in FCF/share from 2027 onwards.
Overall, this is yet another acquisition by TCL (after the A25 and the Westconnex) whose economics I find underwhelming, as well as poorly justified to the investor community.
IMHO & DYOR
- Forums
- ASX - By Stock
- TCL
- Ann: Trading Halt
Ann: Trading Halt, page-9
-
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TCL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.14 |
Change
-0.050(0.38%) |
Mkt cap ! $40.78B |
Open | High | Low | Value | Volume |
$13.17 | $13.19 | $13.04 | $54.55M | 4.156M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 5395 | $13.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.14 | 58062 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4848 | 13.130 |
1 | 4848 | 13.110 |
1 | 4848 | 13.090 |
1 | 26 | 13.070 |
1 | 2424 | 13.060 |
Price($) | Vol. | No. |
---|---|---|
13.150 | 2179 | 2 |
13.160 | 1000 | 1 |
13.180 | 10369 | 4 |
13.190 | 2327 | 2 |
13.200 | 16822 | 4 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
TCL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online